📊 OLMA Key Takeaways
Is Olema Pharmaceuticals, Inc. (OLMA) a Good Investment?
Olema is a pre-commercial pharmaceutical company with no revenue and significant annual operating cash burn of $46M, consuming approximately 1.1 years of available cash reserves. While the balance sheet is strong with $480.5M equity, zero debt, and excellent liquidity, the company remains dependent on uncertain clinical development and regulatory approval with no visible near-term revenue catalysts. The improving loss trajectory (25.5% YoY improvement) is encouraging but insufficient to offset the fundamental challenges inherent in pre-revenue biotech.
Pre‑revenue biotech with very strong liquidity (current/quick ~10x) and no debt, providing near‑term financial flexibility. Fundamentals remain weak with large operating losses (−$178.7M) and heavy cash burn (OCF −$146.7M) driving negative ROE/ROA, despite a 15% YoY EPS improvement. Without revenue, execution depends on disciplined expense management and securing non‑dilutive funding or partnerships to extend runway.
Olema Pharmaceuticals, Inc. Key Strengths (OLMA)
- Exceptional balance sheet strength with $480.5M stockholders equity and zero long-term debt
- Outstanding liquidity position with 10.88x current ratio and minimal near-term financing pressure
- Improving loss trajectory with net income declining 25.5% YoY and EPS improving 15.0% YoY, indicating cost management progress
- Robust liquidity (current and quick ratio 9.95x)
- Zero leverage (Debt/Equity 0.00x)
- Large asset and equity base supporting operations
OLMA Stock Risks: Olema Pharmaceuticals, Inc. Investment Risks
- No revenue generation - entirely pre-commercial with success dependent on pipeline clinical development outcomes
- Limited cash runway of approximately 1.1 years at current $46M annual operating cash burn, requiring future funding or clinical success
- High regulatory and clinical development risk typical of early-stage biotech with no approved commercial products or revenue diversification
- Sustained negative operating cash flow with no revenue
- Dilution risk to fund ongoing R&D and operations
- Uncertain path to profitability (negative ROE/ROA)
Key Metrics to Watch
- Quarterly cash burn rate and path to achieving positive operating cash flow or revenue milestone
- Clinical trial advancement, FDA interactions, regulatory milestones, and competitive pipeline developments
- Operating cash flow (burn) trend
- Total liquid assets (cash + short-term investments) runway
Olema Pharmaceuticals, Inc. (OLMA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.88x current ratio provides a solid financial cushion.
OLMA Profit Margin, ROE & Profitability Analysis
OLMA vs Healthcare Sector: How Olema Pharmaceuticals, Inc. Compares
How Olema Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Olema Pharmaceuticals, Inc. Stock Overvalued? OLMA Valuation Analysis 2026
Based on fundamental analysis, Olema Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Olema Pharmaceuticals, Inc. Balance Sheet: OLMA Debt, Cash & Liquidity
OLMA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Olema Pharmaceuticals, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.20 indicates the company is currently unprofitable.
OLMA Revenue Growth, EPS Growth & YoY Performance
Olema Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
OLMA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Olema Pharmaceuticals, Inc. (CIK: 0001750284)
📋 Recent SEC Filings
❓ Frequently Asked Questions about OLMA
What is the AI rating for OLMA?
Olema Pharmaceuticals, Inc. (OLMA) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 66% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are OLMA's key strengths?
Claude: Exceptional balance sheet strength with $480.5M stockholders equity and zero long-term debt. Outstanding liquidity position with 10.88x current ratio and minimal near-term financing pressure. ChatGPT: Robust liquidity (current and quick ratio 9.95x). Zero leverage (Debt/Equity 0.00x).
What are the risks of investing in OLMA?
Claude: No revenue generation - entirely pre-commercial with success dependent on pipeline clinical development outcomes. Limited cash runway of approximately 1.1 years at current $46M annual operating cash burn, requiring future funding or clinical success. ChatGPT: Sustained negative operating cash flow with no revenue. Dilution risk to fund ongoing R&D and operations.
What is OLMA's revenue and growth?
Olema Pharmaceuticals, Inc. reported revenue of N/A.
Does OLMA pay dividends?
Olema Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find OLMA SEC filings?
Official SEC filings for Olema Pharmaceuticals, Inc. (CIK: 0001750284) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is OLMA's EPS?
Olema Pharmaceuticals, Inc. has a diluted EPS of $-0.52.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is OLMA's fundamental grade?
Based on our AI fundamental analysis in May 2026, Olema Pharmaceuticals, Inc. has a C grade with 66% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is OLMA stock overvalued or undervalued?
Valuation metrics for OLMA: ROE of -11.0% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is OLMA's AI grade for 2026?
Our dual AI analysis gives Olema Pharmaceuticals, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is OLMA's free cash flow?
Olema Pharmaceuticals, Inc.'s operating cash flow is $-46.0M, with capital expenditures of $0.0.
How does OLMA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -11.0% (avg: 15%), current ratio 10.88 (avg: 2).